In light of the conflicting results of previous studies and the lack of significant effect on atherosclerosis development by the Affibody directed against IL-17 activity investigated here, future studies are needed to detail the effect of IL-17 blocking at all stages of atherosclerosis. The gene discussed is IL17A; the disease is atherosclerosis.